These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16613552)

  • 1. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.
    Sokoloff P; Diaz J; Le Foll B; Guillin O; Leriche L; Bezard E; Gross C
    CNS Neurol Disord Drug Targets; 2006 Feb; 5(1):25-43. PubMed ID: 16613552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.
    Guillin O; Griffon N; Bezard E; Leriche L; Diaz J; Gross C; Sokoloff P
    Eur J Pharmacol; 2003 Nov; 480(1-3):89-95. PubMed ID: 14623353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
    Heidbreder C
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of dopamine D₃ receptor neurotransmission in cognition.
    Nakajima S; Gerretsen P; Takeuchi H; Caravaggio F; Chow T; Le Foll B; Mulsant B; Pollock B; Graff-Guerrero A
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):799-813. PubMed ID: 23791072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.
    Maggio R; Millan MJ
    Curr Opin Pharmacol; 2010 Feb; 10(1):100-7. PubMed ID: 19896900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dopamine D3 receptor, a quarter century later.
    Sokoloff P; Le Foll B
    Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
    Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs.
    Pich EM; Collo G
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1437-47. PubMed ID: 26298833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5.
    Chen PC; Lao CL; Chen JC
    J Neurochem; 2009 Aug; 110(4):1180-90. PubMed ID: 19522735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of action of novel antipsychotic drugs.
    Meltzer HY
    Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drugs acting on D3 receptors in neuropsychiatric disorders: facts and prospects. Implication for schizophrenia and its treatment in the regulation of BDNF-dependence on D3 receptor expression].
    Sokoloff P; Leriche L
    Encephale; 2007 Nov; 33(Pt 3):870-2. PubMed ID: 18402360
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin-2-induced increases in climbing behavior: inhibition by dopamine D-1 and D-2 receptor antagonists.
    Zalcman SS
    Brain Res; 2002 Jul; 944(1-2):157-64. PubMed ID: 12106675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
    Collo G; Zanetti S; Missale C; Spano P
    Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.
    Joyce JN
    Pharmacol Ther; 2001; 90(2-3):231-59. PubMed ID: 11578658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
    Presgraves SP; Borwege S; Millan MJ; Joyce JN
    Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions.
    Schwartz JC; Diaz J; Pilon C; Sokoloff P
    Brain Res Brain Res Rev; 2000 Mar; 31(2-3):277-87. PubMed ID: 10719154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.